Evidence map›Paper›PMID 28857649›Full record

Trial reportHuman vaccines & immunotherapeutics2017

Immune responses to oral poliovirus vaccine in HIV-exposed uninfected Zimbabwean infants.

James A Church, Sandra Rukobo, Margaret Govha, Marya P Carmolli, Sean A Diehl, Bernard Chasekwa, Robert Ntozini, Kuda Mutasa, Jean H Humphrey, Beth D Kirkpatrick and 1 more

Open access · hybridAbstract readClinical Trial
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Science advances · 2023
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

James A Churcha Zvitambo Institute for Maternal and Child Health Research , Harare , Zimbabwe.
Sandra Rukoboa Zvitambo Institute for Maternal and Child Health Research , Harare , Zimbabwe.
Margaret Govhaa Zvitambo Institute for Maternal and Child Health Research , Harare , Zimbabwe.
Marya P Carmollic Department of Medicine, Vaccine Testing Center , University of Vermont , Burlington , VT , USA.
Sean A Diehlc Department of Medicine, Vaccine Testing Center , University of Vermont , Burlington , VT , USA.
Bernard Chasekwaa Zvitambo Institute for Maternal and Child Health Research , Harare , Zimbabwe.
Robert Ntozinia Zvitambo Institute for Maternal and Child Health Research , Harare , Zimbabwe.
Kuda Mutasaa Zvitambo Institute for Maternal and Child Health Research , Harare , Zimbabwe.
Jean H Humphreya Zvitambo Institute for Maternal and Child Health Research , Harare , Zimbabwe.
Beth D Kirkpatrickc Department of Medicine, Vaccine Testing Center , University of Vermont , Burlington , VT , USA.
Andrew J Prendergasta Zvitambo Institute for Maternal and Child Health Research , Harare , Zimbabwe.
Zvitambo Institute for Maternal and Child Health Research · ZWUniversity of Vermont · USQueen Mary University of London · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

It remains uncertain whether HIV-exposed uninfected (HEU) infants have impaired responses to oral vaccines. We performed a cross-sectional study of 6-month-old infants recruited at birth to the ZVITAMBO trial in Zimbabwe between 1997-2001, before introduction of prevention of mother-to-child transmission interventions. We measured poliovirus-specific IgA to type 1-3 polio strains by semi-quantitative capture ELISA in cryopreserved serum samples collected from 85 HEU and 101 HIV-unexposed infants at 6 months of age, one month after their last immunisation with trivalent OPV. Almost all infants were breastfed, with the majority in both groups mixed breastfed (70.6% HEU versus 71.3% HIV-unexposed). Median (IQR) vaccine titers for HEU and HIV-unexposed infants were 1592 (618-4896) vs. 1774 (711-5431) for Sabin 1 (P = 0.46); 1895 (810-4398) vs. 2308 (1081-4283) for Sabin 2 (P = 0.52); and 1798 (774-4192) vs. 2260 (996-5723) for Sabin 3 (P = 0.18). There were no significant differences in vaccine titers between HEU and HIV-unexposed infants, suggesting that vertical HIV exposure does not impact oral poliovirus vaccine immunogenicity.

Indexed as

Administration, OralAdultAntibodies, ViralCross-Sectional StudiesEnzyme-Linked Immunosorbent AssayFemaleHIV InfectionsHumansImmunoglobulin AInfantInfectious Disease Transmission, VerticalMaleMothersPoliomyelitisPoliovirusPoliovirus Vaccine, OralAntibodies, ViralImmunoglobulin APoliovirus Vaccine, OralAfricaHIVinfantsOPVoral vaccinepoliovirus

Identifiers

PMID28857649
PMCPMC5703368
OpenAlexW2753628836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.